3D Medicines (HKG: 1244), a China-based oncology specialist, has announced the registration of its PD-L1 monoclonal antibody (mAb) envafolimab in Macau. The approval designates envafolimab for the treatment of unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors.
Envafolimab is notable for being the world’s first single-domain PD-L1 antibody and a human IgG1 Fc fusion protein that can be administered subcutaneously. It received approval in China in November 2021 for treating unresectable or metastatic advanced solid tumors with MSI-H/dMMR.- Flcube.com
